Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions

Example Group: ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis

Generated Narrative: Group

Resource Group "179785" Version "4" Updated "2023-12-04 20:30:06+0000"

Profile: ComparatorDefinition

Artifact related artifact:

Artifact Title: ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis

Artifact URL: https://fevir.net/resources/Group/179785

Artifact Publisher: Computable Publishing LLC

Artifact Copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

Artifact Contact: support@computablepublishing.com

Artifact Author: Brian S. Alper:

CombinationMethod: any-of

modifierExtension[http://hl7.org/fhir/StructureDefinition/artifact-status]

identifier: FEvIR Object Identifier: 179785

type: animal

membership: definitional

name: ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis

description: Description: usual-care pharmacologic thromboprophylaxis Note: Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice. Note: Usual-care pharmacological thromboprophylaxis included both intermediate-intensity (in 27%) and prophylactic-intensity dosing (in 72%). Subgroup analyses may be informative to determine if there is a difference related to the intensity used in the control arm of the trial.

characteristic

CharacteristicDescription: ATTACC comparator arm

CharacteristicTiming

url

contextCode

value: Start of trial ()

url

offset

value: 0-14

url

text

value: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.

code: Defined by CodeableConcept ()

value: Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be more than half of the approved therapeutic dose for the treatment of venous thromboembolism. ()

exclude: false

characteristic

CharacteristicDescription: ACTIV-4a comparator arm

CharacteristicTiming

url

contextCode

value: Start of trial ()

url

offset

value: 0-14

url

text

value: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.

code: Defined by CodeableConcept ()

value: Any one of enoxaparin, dalteparin, tinzaparin, fondaparinux, or heparin according to local preference. Dose of agent specified to be consistent with guidelines for low dose thromboprophylaxis. ()

exclude: false

characteristic

CharacteristicDescription: REMAP-CAP comparator arm

CharacteristicTiming

url

contextCode

value: Start of trial ()

url

offset

value: 0-14

url

text

value: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.

code: Defined by CodeableConcept ()

value: Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be sufficient to result in therapeutic anticoagulation. ()

exclude: false